Skip to main content
ARIX BIOSCIENCE PLC logo

ARIX BIOSCIENCE PLC — Investor Relations & Filings

Ticker · ARIX ISIN · GB00BD045071 LEI · 213800OVT3AHQCXNIX43 IL Financial and insurance activities
Open in API
Filings indexed 547 across all filing types
Latest filing 2022-10-05 Director's Dealing
Country GB United Kingdom
Listing IL ARIX

About ARIX BIOSCIENCE PLC

https://www.arixbioscience.com/

Arix Bioscience plc is a global venture capital company that specializes in the biotechnology and life sciences sectors. The firm's primary activity involves investing in and building innovative biotech companies, providing capital and strategic support from early stages, including seed, preclinical, and clinical development. Arix focuses on identifying and nurturing breakthrough advances in life sciences to accelerate the development of new medical technologies and therapies. According to public information, the company has entered into a process of liquidation.

Recent filings

Filing Released Lang Actions
Director/PDMR Shareholding
Director's Dealing Classification · 1% confidence The document explicitly details a 'Director/PDMR Shareholding' notification. It reports that a Director and Chairman, Peregrine Moncreiffe, purchased a specific number of Ordinary shares. This type of filing, which reports personal share transactions by company directors and executives (insider trades), directly corresponds to the definition of 'Director's Dealing'. Therefore, the appropriate filing code is DIRS.
2022-10-05 English
Arix Portfolio Company Aura Biosciences Presents Interim Phase 2 Data Highlighting Belzupacap Sarotalocan (AU-011) Suprachoroidal Efficacy and Safety at AAO 2022
Regulatory Filings Classification · 1% confidence The document is a press release disseminated via EQS Group, announcing that Arix Bioscience's portfolio company, Aura Biosciences, presented interim Phase 2 clinical trial data at the AAO 2022 meeting. The content focuses on clinical trial results, safety profiles, and efficacy data for a drug candidate (belzupacap sarotalocan). This type of announcement, detailing clinical progress and data presentation, is characteristic of an Earnings Release (ER) or a general Regulatory Announcement/Filing (RNS). Since it is a specific announcement of clinical data presentation rather than a comprehensive financial report (10-K, IR) or a management discussion (MDA), and it is not a proxy statement (DEF 14A) or a dividend notice (DIV), the most fitting category for a material, time-sensitive update that isn't a full financial report is Earnings Release (ER), as clinical trial updates often accompany or substitute for standard earnings commentary in biotech/pharma. However, given the structure (dissemination of a 'Regulatory Announcement' via EQS, focusing purely on clinical data presentation rather than quarterly financial figures), it strongly aligns with a general regulatory update. Since 'ER' usually implies quarterly financial results, and this is a specific clinical data update, 'RNS' (Regulatory Filings/General Regulatory Announcement) serves as the best fit for a non-standard, material disclosure that isn't covered by other specific codes like DIV, CAP, or MANG. The document length is substantial (12764 chars), so it is not an RPA.
2022-10-03 English
Unaudited NAV for August 2022
Net Asset Value Classification · 1% confidence The document explicitly states 'Unaudited NAV for August 2022' and provides a table detailing the 'Total NAV' and 'NAV per share' as of August 31, 2022. This directly corresponds to the definition of Net Asset Value (NAV) updates, which is classified under the code NAV.
2022-09-15 English
Unaudited NAV for July 2022
Net Asset Value Classification · 1% confidence The document explicitly states 'Unaudited NAV for July 2022' and provides a table detailing the 'Total NAV' and 'NAV per share' as of '31 July 22 (unaudited)'. This content directly corresponds to the definition of a Net Asset Value update, which is classified as 'Fund Information / Factsheet' (FS) or specifically 'Net Asset Value' (NAV). Given the specific definition for NAV (Code: NAV), this is the most appropriate classification. The document is short and presents the core data directly, not just announcing a separate report.
2022-08-12 English
Artios initiates Phase 2 study of Polθ Inhibitor ART4215 in Combination with PARP Inhibitor Talazoparib in BRCA Deficient Breast Cancer
Regulatory Filings Classification · 1% confidence The document is a press release disseminated via the National Storage Mechanism (NSM) and EQS Group, dated August 10, 2022. It announces that Arix Bioscience's portfolio company, Artios Pharma, has initiated a Phase 2 study for a drug candidate (ART4215). This type of announcement, detailing clinical trial progress and scientific updates, is typically classified as an Investor Presentation (IP) if it were a deck, or an Earnings Release (ER) if it were financial results. However, since this is a specific operational/clinical update that is not a formal financial report (10-K, IR, ER), and it contains detailed scientific and trial information intended for investors, it aligns best with an Investor Presentation (IP) or a general Regulatory Filing (RNS). Given the detailed nature of the clinical trial update and the inclusion of quotes from management and principal investigators, it functions as a key piece of investor information. Since it is not a formal financial report, and it is not a simple announcement of a report's publication (RPA), the most fitting category for detailed operational/clinical news is often IP, but RNS serves as the best general regulatory announcement fallback. Upon review of the definitions, this is a specific regulatory announcement about clinical progress, which often falls under RNS if a more specific category like 'LTR' (Legal) or 'CAP' (Financing) doesn't apply. Since it is a general regulatory announcement disseminated via the NSM, RNS is the most appropriate general classification for non-financial, non-management change regulatory news.
2022-08-10 English
Portfolio Company Disc Medicine Enters Definitive Merger Agreement with Gemini Therapeutics
M&A Activity Classification · 1% confidence The document is a regulatory announcement disseminated via EQS Group, dated August 10, 2022. It details a significant corporate action: Arix Bioscience's portfolio company, Disc Medicine, entering a definitive merger agreement with Gemini Therapeutics. This announcement discusses financing, clinical trial updates (Phase 2 study initiation), and provides extensive background on the companies involved. This type of material, which announces a major corporate transaction (merger/acquisition) and related financing/pipeline updates, fits best under the category of M&A Activity (TAR). It is not a full annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS), as it specifically concerns a takeover/merger proposal.
2022-08-10 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.